Verzenio Side Effects
Generic name: abemaciclib
Note: This document contains side effect information about abemaciclib. Some dosage forms listed on this page may not apply to the brand name Verzenio.
Applies to abemaciclib: oral tablets.
Side effects include:
In combination with an aromatase inhibitor (i.e., anastrozole or letrozole) for initial treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer: Diarrhea, neutropenia, fatigue, infection (most commonly upper respiratory tract infection, lung infection, and pharyngitis), nausea, abdominal pain, anemia, vomiting, alopecia, decreased appetite, leukopenia, constipation, rash, cough, pruritus, dyspnea, dizziness, decreased weight, influenza-like illness, thrombocytopenia, elevated Scr concentrations (see Renal Impairment under Cautions), decreased lymphocyte count, elevated AST and/or ALT concentrations, decreased platelet count.
In combination with fulvestrant for treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in patients with disease progression following endocrine therapy: Diarrhea, fatigue, neutropenia, nausea, infection (includes urinary tract and upper respiratory tract infection, lung infection, pharyngitis, conjunctivitis, sinusitis, vaginal infection, sepsis), abdominal pain, anemia, leukopenia, decreased appetite, vomiting, headache, dysgeusia, alopecia, thrombocytopenia, stomatitis, cough, pruritus, constipation, dizziness, peripheral edema, pyrexia, rash, decreased weight, myasthenia, elevated Scr concentrations (see Renal Impairment under Cautions), decreased lymphocyte count, decreased platelet count, elevated AST and/or ALT concentrations.
Monotherapy in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy for metastatic disease: Diarrhea, fatigue, nausea, decreased appetite, abdominal pain, neutropenia, vomiting, infection, anemia, headache, thrombocytopenia, cough, constipation, leukopenia, arthralgia, decreased weight, dry mouth, stomatitis, alopecia, dysgeusia, dizziness, pyrexia, dehydration, elevated Scr concentrations (see Renal Impairment under Cautions), decreased leukocyte count, decreased neutrophil count, decreased lymphocyte count, elevated AST and/or ALT concentrations, hypokalemia, hyponatremia.
For Healthcare Professionals
Applies to abemaciclib: oral tablet.
General
The most common adverse reactions reported (20% or greater incidence) were increased creatinine (98%), decreased white blood cell count (91%), diarrhea (90%), decreased neutrophil count (88%), anemia (84%), fatigue/asthenia (65%), nausea (64%), decreased lymphocyte count (63%), decreased platelet count (53%), neutropenia (46%), decreased appetite (45%), infections (43%), increased ALT (41%), abdominal pain (39%), increased AST (37%), vomiting (35%), leukopenia (28%), and thrombocytopenia (20%).[Ref]
Renal
Very common (10% or more): Increased creatinine (98%)[Ref]
Hematologic
Very common (10% or more): Decreased white blood cell count (91%), decreased neutrophil count (88%), anemia (84%), decreased lymphocyte count (63%), decreased platelet count (53%), neutropenia (46%), leukopenia (28%), thrombocytopenia (20%)
Common (1% to 10%): Febrile neutropenia, lymphopenia
Frequency not reported: Neutropenic sepsis[Ref]
Gastrointestinal
Very common (10% or more): Diarrhea (85%), nausea (64%), abdominal pain (39%), vomiting (28%), constipation (17%), stomatitis (15%), dry mouth (14%)[Ref]
Other
Very common (10% or more): Fatigue/asthenia (65%), infections (43%), peripheral edema (12%), pyrexia (11%)[Ref]
Metabolic
Very common (10% or more): Decreased appetite (27%), decreased weight (14%), dehydration (10%)[Ref]
Hepatic
Very common (10% or more): Increased ALT (41%), increased AST (37%)[Ref]
Respiratory
Very common (10% or more): Cough (19%)
Common (1% to 10%): Interstitial lung disease, pneumonitis[Ref]
Nervous system
Very common (10% or more): Headache (20%), dysgeusia (14%), dizziness (13%)[Ref]
Dermatologic
Very common (10% or more): Alopecia (21%), pruritus (14%), rash (13%)[Ref]
Musculoskeletal
Very common (10% or more): Arthralgia (15%)[Ref]
Cardiovascular
Common (1% to 10%): Venous thromboembolic events[Ref]
Immunologic
Very common (10% or more): Infections (44%)
Frequently asked questions
- What type of drug is Verzenio?
- Is Verzenio better than Ibrance?
- Can you take Verzenio after Ibrance fails?
- How long do you take Verzenio for?
- How long does it take Verzenio to work?
- Is Verzenio (abemaciclib) a chemo drug?
- How effective is Verzenio?
More about Verzenio (abemaciclib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (7)
- Drug images
- Latest FDA alerts (1)
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: CDK 4/6 inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
References
1. "Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company (2017):
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.